Skip to content

Stereotaxis STXS Accrued Liabilities, Current

Accrued Liabilities, Current at other companies

Boston Scientific logo
Boston ScientificBSX
$2.51B+6.8%
ITG
Integer HoldingsITGR
Merit Medical Systems logo
Merit Medical SystemsMMSI
IAR
Integra LifeSciencesIART
Neuropace, Inc. logo
Neuropace, Inc.NPCE
Neuronetics logo
NeuroneticsSTIM

Other financials

Income statement

See full
Revenue$6.3M-15.8%
Gross profit$3.8M-6.6%
Operating income-$6.0M-0.9%
Net income-$5.9M-0.7%
EPS (diluted)-$0.06+14.3%

Balance sheet

See full
Cash & equivalents$14.6M+36.7%
Total debt$5.3M-10.0%
Total equity$14.4M+399%
Total assets$54.0M+18.2%

Cash flow

See full
Operating cash flow-$3.4M-93.5%
CapEx$79.0K
Free cash flow-$3.5M

Valuation

See full
Market cap$168.11M-11.6%
Enterprise value$158.77M-15.9%
P/S5.4×-0.6×

Profitability

See full
Gross margin53.9%+0.5pp
Operating margin-71%-14.0pp
Net margin-69.5%-13.7pp
FCF margin-35.5%-2.4pp

Returns & leverage

See full
Return on equity-251.5%-29.9pp
Debt / equity0.4×-1.7×
Current ratio1.6×+0.5×

Where this comes from

Reported directly by Stereotaxis in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Stereotaxis’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stereotaxis's accrued liabilities, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Stereotaxis's accrued liabilities, current?
Stereotaxis (STXS) reported accrued liabilities, current of $1.48M in Q1 2026.
How has Stereotaxis's accrued liabilities, current changed year-over-year?
Stereotaxis's accrued liabilities, current decreased by 49.5% year-over-year, from $2.93M to $1.48M.
What is the long-term trend for Stereotaxis's accrued liabilities, current?
Over 5 years (2020 to 2025), Stereotaxis's accrued liabilities, current has grown at a -8.4% compound annual growth rate (CAGR), from $3.21M to $2.07M.